Safety of benzophenone to be used as flavouring by EFSA Panel on Food Contact Materials Enzymes, Flavourings and Processing Aids (CEF) et al.
SCIENTIFIC OPINION
ADOPTED: 20 September 2017
doi: 10.2903/j.efsa.2017.5013
Safety of benzophenone to be used as ﬂavouring
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF),
Vittorio Silano, Claudia Bolognesi, Laurence Castle, Kevin Chipman, Jean-Pierre Cravedi,
Karl-Heinz Engel, Paul Fowler, Roland Franz, Konrad Grob, Rainer G€urtler, Trine Husøy,
Sirpa K€arenlampi, Maria Rosaria Milana, Karla Pfaff, Gilles Riviere,
Jannavi Srinivasan, Maria de Fatima Tavares Pocas, Christina Tlustos, Detlef W€olﬂe,
Holger Zorn, Romualdo Benigni, Mona-Lise Binderup, Leon Brimer, Francesca Marcon,
Daniel Marzin, Pasquale Mosesso, Gerard Mulder, Agneta Oskarsson, Camilla Svendsen,
Maria Anastassiadou, Maria Carfı, Siiri Saarma and Wim Mennes
Abstract
Benzophenone [FL-no: 07.032] has been evaluated as a ﬂavouring substance, in FGE.69, by the EFSA
Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food in 2008.
Benzophenone was evaluated also by JECFA (2011) and by IARC (2013) based on studies that were not
considered in the EFSA opinion on FGE.69. Therefore, the Commission requested the CEF Panel to carry
out a review of existing literature on the safety of this ﬂavouring substance. In the framework of the
evaluation of benzophenone as a food contact material, the CEF Panel established a tolerable daily
intake (TDI) of 0.03 mg/kg body weight (bw) per day (2009). In the present Opinion, the
Panel considered the already existing evaluations by EFSA, JECFA, IARC and available literature data on
benzophenone toxicity. Moreover, new data on the use levels of benzophenone as a ﬂavouring substance
have been provided. The Panel considers that there is no concern with respect to genotoxicity. The
Panel considers the endocrine activities of benzophenone and its metabolite 4-hydroxybenzophenone as
weak and not directly related to the observed toxic effects including the neoplastic effects in rodents.
The Panel conﬁrms that the conservative approach taken by EFSA (2009) to derive a TDI of 0.03 mg/kg
bw for benzophenone is appropriate to cover the non-neoplastic effects in the chronic toxicity studies
and the neoplastic effects induced in the rodent carcinogenicity studies. The TDI is in the same order of
magnitude as the chronic dietary exposure of adults and children to benzophenone (10–20 lg/kg bw per
day) for the amount of added ﬂavouring substance. The Panel considers that the calculated TDI and
exposure estimate are based on conservative assumptions. The Panel concludes that there is no safety
concern for benzophenone under the current condition of use as a ﬂavouring substance.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The use of ﬂavourings is regulated under Regulation (EC) No 1334/20081 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122.
The substance benzophenone, [FL no. 07.032] (CAS No. 119-61-9) is currently included in this
Union List. It is a substance which is not currently under evaluation. This substance is also known as
diphenyl ketone. This substance was included in the Union list on the basis of the EFSA evaluation in
FGE 69 of 2008. FGE 69 includes this substance. Benzophenone was evaluated by JECFA as a
ﬂavouring substance, with JECFA No. 831. The studies evaluated by IARC were not considered in the
EFSA opinion on FGE 69. There may be also additional studies on the safety of this substance.
The substance ethyl acrylate, [FL no. 09.037], (CAS No. 140-88-5) was included in the Union list on
the basis of the EFSA evaluation in FGE 71 of 2010. FGE 71 includes this substance. Ethyl acrylate was
evaluated by JECFA as a ﬂavouring substance, with JECFA No. 1351. The studies evaluated by IARC
were not considered in the EFSA opinion of FGE 71. There may be also additional studies on the safety
of this substance.
1.1.2. Terms of Reference
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/20023, the European Commission
requests the European Food Safety Authority (EFSA) to carry out a review of existing published literature
on the safety of the ﬂavouring substances benzophenone, [FL. No 07.032], (CAS No. 119-61-9) and ethyl
acrylate, [FL 09.037], (CAS No. 140-88-5), and advise on their safety when used as ﬂavouring
substances.
1.2. Interpretation of the Terms of Reference
Since benzophenone [FL- no: 07.032] and ethyl acrylate [FL-no: 09.037] are not structurally related
and were evaluated in different FGEs (FGE.69 and FGE.71), they will be evaluated in separate
opinions. The present document will address the question of the Commission on benzophenone.
Meanwhile, EFSA has also received information on use levels which will be taken into consideration.
Considering the Terms of Reference, the Panel will not address in this assessment, the exposure that
may result from the use as food contact material.
In respect to the approach to be followed for the assessment of benzophenone used as a
ﬂavouring substance, the Panel was of the view that previous assessments should be used as starting
points for this scientiﬁc opinion. The previous assessment will be updated with new information that is
connected to the concerns identiﬁed in the background (Section 1.1).
In the background (Section 1.1), it is especially mentioned that the studies evaluated by IARC in
the report on carcinogenicity of benzophenone from 2013 were not considered in the EFSA evaluation
from 2008, and that there may be additional studies on the safety of benzophenone when used as a
ﬂavouring substance. Thus, the present evaluation is mainly focusing on the genotoxicity and
carcinogenicity of benzophenone, in addition to considering any new data on toxicity, especially effects
on the endocrine system, which may have an impact on the safety assessment of benzophenone as
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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ﬂavouring. In addition, previous assessments of benzophenone by JECFA (2011) and EFSA (2009) are
brieﬂy presented. A number of benzophenone derivatives are used as UV-ﬁlters in sunscreens;
however, the safety of these compounds will not be assessed in the present evaluation, which will
focus on benzophenone, the compound used as a ﬂavouring substance.
1.3. Information on evaluations from other organisations
In the JECFA report on ‘Aromatic substituted secondary alcohols, ketones and related esters’ (JECFA,
2011), additional eight substances were evaluated and new carcinogenicity data (NTP, 2006) which have
become available since JECFA evaluated benzophenone at their 57th meeting (2001) were included.
The European Chemical Agency (ECHA) issued a Decision on Substance Evaluation for
benzophenone (ECHA, 2015) in which oestrogenic, anti-androgenic and thyroidal activities of the
substance were addressed. While ECHA acknowledged that the submitted long-term studies on
benzophenone did not provide evidence for ‘endocrine disruption due to its estrogenic properties’, it
was also outlined that these studies did not include some endpoints (e.g. on mammary gland histology
or follicular maturation) which are ‘especially sensitive to estrogenic substances’. The EFSA Panel on
Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) noted that the ECHA
document was mainly focussed on aquatic toxicity and the studies on endocrine activities were already
discussed in the previous EFSA opinion (EFSA, 2009).
The endocrine effects of benzophenone and its metabolites were also discussed by IARC (2013) as
potential mechanisms of tumour induction. Based on the results from NTP carcinogenicity studies (NTP,
2006), IARC (2013) concluded that there was sufﬁcient evidence in experimental animals for
carcinogenicity and classiﬁed benzophenone as possibly carcinogenic to humans (Group 2B).
2. Data and methodologies
The search for literature was done by EFSA on benzophenone [FL-no: 07.032] to review existing
literature on the safety of this substance and to advise on its safety when used as ﬂavouring
substance. A literature search was carried out through Web of Science database, until August 2017,
using keywords ‘benzophenone’ or ‘119-61-9’ and ‘genotox*’, ‘canc*’, ‘carc*’, ‘tumor*’, ‘toxicokin*’,
‘metabol*’, ‘absorb*’, ‘distrib*’, ‘excret*’, ‘estrogen*’, ‘endocr*’, ‘diet*’ and ‘reproduct*’ while searching
in ‘all databases’. Additional searches were carried out through Scopus database, using the keyword
combination of ‘benzophenone’ and ‘tox’, and the database of Decernis, using the keyword ‘119-61-9’.
3. Procedure of the safety assessment
3.1. Assessment
The Panel considered studies already evaluated (EFSA, 2008, 2009; JECFA, 2011) and new data
from literature search. Except for genotoxicity, no new relevant studies were identiﬁed for short-term
toxicity, chronic toxicity and carcinogenicity.
3.2. Technical data
Information on identity of the substance and speciﬁcations are based on data already described in
FGE.69 (EFSA, 2008) and are presented in Table 1.
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Table 1: Summary of speciﬁcations for the substance benzophenone (EFSA, 2008)
FL-no
JECFA-no
EU Register
name
Structural
formula
FEMA no
CoE no
CAS no
Phys. form
Mol. formula
Mol. weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index(d)
Spec. gravity(e)
07.032
831
Benzophenone O 2134
166
119-61-9
Solid
C13H10O
182.22
Insoluble
Very soluble
305
48
IR
98%
n.a.
n.a.
FL-no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract
Service; IR: infrared spectroscopy; n.a.: not applicable.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1,013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
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3.3. Information on existing evaluations from EFSA
Benzophenone [FL-no: 07.032] has been evaluated by JECFA (2002). EFSA considered this
evaluation and concluded, in FGE.69, that benzophenone is of no safety concern at estimated level of
intake as ﬂavouring substance based on the Maximised Survey-derived Daily Intake (MSDI) approach
(EFSA, 2008).
Benzophenone is also used as an additive in food contact materials (FCM) and was evaluated by
the CEF Panel in 2009 (EFSA, 2009). The Panel considered that the non-neoplastic kidney effects
observed in male rats (NTP, 2006) were adverse and applied a benchmark dose (BMD) analyses on
this endpoint, deriving a tolerable daily intake (TDI) of 0.03 mg/kg body weight (bw).
3.4. Exposure
3.4.1. Concentration in processed and non-processed foods from natural sources
Benzophenone [FL-no: 07.032] has been reported to occur in bullocks heart, cherimoya, grape,
mountain papaya, passion fruit, soursop, tea and vanilla (Triskelion, 2017). Quantitative data are
reported for benzophenone in mountain papaya (< 0.01 mg/kg), passion fruit (0.045 mg/kg), grape
(up to 0.13 mg/kg) and vanilla (up to 0.48 mg/kg) (Triskelion, 2017).
3.4.2. Chronic dietary exposure
The exposure assessment to be used in the Procedure for the safety evaluation of the candidate
substance is the chronic added portions exposure technique (APET) estimate (EFSA CEF Panel, 2010).
The chronic APET for benzophenone has been calculated for adults and children (see Table 2 and
Appendix C). The chronic APET calculation is based on the combined normal occurrence level.
The Panel noted that the contribution from natural occurrence of benzophenone to the overall
exposure is approximately 3–5% of the APET.
The Panel noted that there are other sources of exposure, e.g. from FCM as described in the EFSA
2009 opinion. According to Regulation (EU) 10/20114 on plastics, benzophenone has a speciﬁc
migration limit (SML) of 0.6 mg/kg food corresponding to a maximum exposure of 600 lg/person per
day. Based on this SML, the maximum exposure to benzophenone from FCM would be one-third of the
present TDI (0.03 mg/kg bw per day). The Panel considers that the calculated TDI is conservative and
that the exposure data is based on worst-case scenarios.
3.4.3. Acute dietary exposure
Acute exposure is not evaluated, because this opinion addresses only chronic exposure.
Table 2: APET – Chronic dietary exposure
Chronic APET
Added(a) Other dietary sources(b) Combined(c)
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
lg/kg bw
per day
lg/person
per day
Adults(d) 8.5 512 0.30 18.2 8.5 512
Children(e) 22 323 0.76 11.5 22 323
APET: added portions exposure technique; bw: body weight.
(a): APET Added is calculated on the basis of the normal amount of ﬂavouring added to a speciﬁc food category.
(b): APET Other Dietary Sources is calculated based on the natural occurrence of the ﬂavouring in a speciﬁed food category.
(c): APET Combined is calculated based on the combined amount of added ﬂavouring and naturally occurring ﬂavouring in a
speciﬁed food category.
(d): For the adult APET calculation, a 60-kg person is considered representative.
(e): For the child APET calculation, a 3-year-old child with a 15 kg bw is considered representative.
4 Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into contact
with food. OJ L 12, 15.1.2011, p. 1–89.
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3.5. Biological and toxicological data
3.5.1. Absorption, distribution, metabolism and excretion
A rapid absorption of benzophenone [FL-no: 07.032] from the gastrointestinal tract in rats was
observed after a single oral dose of 100 mg/kg bw (Jeon et al., 2008).
The metabolism of benzophenone has been investigated in vitro in freshly isolated rat hepatocytes
(Nakagawa et al., 2000) and in rats (Nakagawa and Tayama, 2002; Jeon et al., 2008). In rat
hepatocytes, benzophenone was converted to benzhydrol, 4-hydroxybenzophenone and the sulphate
conjugate of 4-hydroxybenzophenone (Nakagawa et al., 2000).
Also in vivo, benzhydrol and 4-hydroxybenzophenone were reported to be the main metabolites in
male rats (Figure 1) after a single oral dose of 100 mg/kg bw (Jeon et al., 2008). The same two
metabolites were identiﬁed in plasma of female rats after oral doses of 100 and 400 mg/kg bw with
benzhydrol being the major metabolite (Nakagawa and Tayama, 2002).
Overall, from studies in rats benzophenone has been demonstrated to be rapidly absorbed in the
gastrointestinal tract and metabolised mainly to benzhydrol and 4-hydroxybenzophenone.
3.5.2. Short-term and subchronic toxicity
Short-term animal studies, previously described in the EFSA scientiﬁc opinion (2009), suggested
that the liver and kidneys were target organs for benzophenone toxicity, as well as the haematopoietic
system (USEPA, 1984; Burdock et al., 1991). In 14-week toxicity studies by NTP (2000), evaluated by
EFSA (2009) and JECFA (2011), B6C3F1 mice and F344/N rats were exposed to benzophenone in feed
at concentrations of 0, 1,250, 2,500, 5,000, 10,000 and 20,000 mg/kg. The highest dose was
unpalatable and most of the animals either died or were terminated for humane reasons.
In mice, these concentrations were estimated by the authors to correspond to a daily intake of 0, 200,
800, 400, 1,600 or 3,300 mg/kg bw for males and 0, 270, 540, 1,000, 1,900 or 4,200 mg/kg bw for
females. The kidney weight was increased in both sexes exposed to 2,500 mg/kg feed. Increased liver
weight in all dose groups was associated with centrilobular hypertrophy of hepatocytes and induction of
CYP2B enzymes by benzophenone, which may be considered an adaptive response of the liver to
Benzophenone
Benzhydrol
4-Hydroxybenzophenone
Figure 1: Proposed metabolism of benzophenone in rats (Nakagawa and Tayama, 2002; Jeon et al., 2008)
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treatment. Based on the increases in kidney weights, JECFA (2011) considered the no observed adverse
effect level (NOAELs) in mice to be 200 mg/kg bw per day (males) and 270 mg/kg bw per day (females).
In the 14-week NTP oral rat study, the doses were 0, 75, 150, 300, 700 or 850 mg/kg bw per day
in males and 0, 80, 160, 300, 700 or 1,000 mg/kg bw per day in females, as estimated by the
authors. Treatment-related increases in liver and kidney weights were reported in all exposed groups,
except the kidney weight in females at the lowest dose. Histopathological changes were observed in
the liver (hypertrophy and/or cytoplasmic vacuolisation of hepatocytes) and the kidney (tubule
dilatation and foci of tubule regeneration). Benzophenone-induced increases in CYP2B activity were
reported. Anaemia, as indicated by decreased haematocrit values, haemoglobin concentrations and
erythrocyte levels, was observed in males and females exposed to 150 and 160 mg/kg bw per day and
higher, respectively. The authors considered the haematological effects to be ‘of minimal severity’
and not ‘clinically relevant’. However, they also mentioned that dehydration may have masked the
severity of anaemia. Based on the haematological ﬁndings, JECFA considered the NOAELs in rats to be
75 mg/kg bw per day (males) and 80 mg/kg bw per day (females).
Overall, the above-mentioned studies in mice and rats together with the already discussed (EFSA,
2009) short-term/subchronic studies in rats (USEPA, 1984; Burdock et al., 1991) have demonstrated
that the liver, kidney and haematopoietic system are targets for benzophenone toxicity. The
Panel noted that increased liver and kidney weights along with microscopic changes were observed in
all dose groups, except in the 20 mg/kg bw per day group in the Burdock study. While the liver effects
were considered to be adaptive changes (Maronpot et al., 2010; Hall et al., 2012), the Panel took a
conservative approach concerning the kidney effects in the male rat because there is still an ongoing
debate on the relevance of rat kidney effects for humans (Melnick et al., 2012; Hard et al., 2013).
Taking these considerations into account, the lowest dose in the 14-week NTP study (75 and 80 mg/kg
bw per day for male and female rats, respectively) was considered a lowest-observed-adverse-effect
level (LOAEL).
3.5.3. Genotoxicity
Summary of in vitro data assessed in FGE.69
Benzophenone evaluation in FGE.69 was based on JECFA (2002).
No reverse mutation was reported in the standard Ames assay with various strains of Salmonella
Typhimurium (TA98, TA100, TA1535, TA1537 and TA1538,) incubated with 3–1,000 lg/plate of
benzophenone [FL-no: 07.032] (Mortelmans et al., 1986; Appendix A, Table A.1).
In vitro data not previously considered
Benzophenone and its metabolites benzhydrol and 4-hydroxybenzophenone induced umu gene
expression, which may be indicative of DNA damage in S. Typhimurium TA1535/pSK1002 when tested
in the presence of recombinant human P450s expressed on Escherichia coli membranes (Takemoto
et al., 2002); in the same study, negative results were obtained with human, rat or mouse
microsomes, as well as with human liver S9 and cytosolic fractions, suggesting the detoxication of
P450-mediated metabolites by other enzymes present in liver preparations. Overall, the relevance for
genotoxicity assessment of the positive ﬁndings reported by Takemoto et al. (2002) is limited in view
of the artiﬁcial metabolic activation system used.
Benzophenone was tested in the SOS/umuC assay in the range of 7.81–1,000 mg/mL (Kotnik et al.,
2016). It showed positive results at the highest concentration only in the presence of metabolic
activation with rat S9. The Panel noted that the umu assay (Takemoto et al., 2002; Kotnik et al., 2016)
is an indicator assay, it is not a validated method for the evaluation of bacterial gene mutation and it is
not one of the assays recommended by the EFSA Scientiﬁc Committee for genotoxicity assessment
(EFSA Scientiﬁc Committee, 2011).
Negative results were reported with benzophenone in a mammalian mutation assay with mouse
lymphoma L5178Y/tk+/ cells (CCRIS, 2009).
Benzophenone at a concentration range of 8.9–142.8 lg/mL (up to 80% inhibitory concentration
(IC80)) in the presence and absence of metabolic activation, did not induce a signiﬁcant increase in
mutation frequencies in L5178Y (tk+/) mouse lymphoma cell line (Jeon et al., 2007).
These studies are summarised in Appendix B, Table B.1.
Summary of in vivo data assessed in FGE.69
No data available.
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In vivo data not previously considered
In male B6C3F1 mice, intraperitoneal treatment with 0, 200, 300, 400 and 500 mg benzophenone/kg
body weight (three injections at 24-h intervals) did not induce statistically signiﬁcant increase in
the frequencies of micronucleated polychromatic erythrocytes (PCEs) in bone marrow (NTP, 2006).
No increases in micronucleated normochromatic erythrocytes were observed in peripheral blood of
male or female mice administered benzophenone for 14 weeks in feed over a concentration range of
1,250–20,000 ppm. No signiﬁcant alterations in the percentage of PCEs among total erythrocytes were
noted in either micronucleus test, indicating no toxicity to the bone marrow from benzophenone
treatment (NTP, 2006).
Benzophenone administered intraperitoneal as a single dose at 0, 500, 1,000 and 2,000 in CBA
mice and at 0,100, 250, 400 and 600 mg/kg bw in NMRI male mice did not induce increase in the
frequency of micronucleated PCEs in peripheral blood, evaluated using the ﬂow cytometer-based assay.
No signiﬁcant decrease in %PCE was associated with benzophenone treatment (Abramsson-Zetterberg
and Svensson, 2011).
These studies are summarised in Appendix B, Table B.2.
Conclusion on genotoxicity
Overall, the Panel considered that based on the available data, which covers all relevant genetic
endpoints (i.e. gene mutations, structural and numerical chromosomal aberrations) there is no concern
with respect to genotoxicity of benzophenone.
3.5.4. Chronic toxicity and carcinogenicity
In toxicity and carcinogenesis studies by NTP (2006; Rhodes et al., 2007), evaluated by EFSA
(2009) and JECFA (2011), mice and rats were exposed during 105 weeks to benzophenone in feed at
concentrations of 0, 312, 625 and 1,250 mg/kg.
In mice the corresponding doses, estimated by the authors, were 40, 80 and 160 mg/kg bw per
day in males and 35, 70 and 150 mg/kg bw per day in females. Statistically signiﬁcant increases in
centrilobular hepatocyte hypertrophy were observed in all exposed groups of mice. Increased
incidences of hepatocellular adenoma (including multiple adenomas) were reported in the high- and
mid-dose groups in males. Incidence of kidney nephropathy was increased in all dose groups of female
mice and there was a dose-related increase in the severity of nephropathy in males.
The corresponding doses in rats were 15, 30 and 60 mg/kg bw per day in males and 15, 30 and
65 mg/kg bw per day in females. Statistically signiﬁcant increases in centrilobular hepatocyte
hypertrophy were observed in all exposed groups of rats and in females there was also an increased
incidence of bile duct hyperplasia in all treated groups. In male rats, there was a positive trend in the
incidence of renal tubule adenoma, associated with a signiﬁcantly increased incidence of renal tubule
hyperplasia in the mid- and high-dose groups. In males, the severity of chronic nephropathy increased
with dose and the increases were statistically signiﬁcant in all exposed groups compared to controls. In
females, the severity of nephropathy was signiﬁcantly increased in the mid- and high-dose groups.
Increased incidence of mononuclear cell leukaemia was observed in male rats in the low- and mid-
dose groups and in female rats in the mid-dose group. Rare histiocytic sarcomas were seen in female
rats and mice in the two higher dose groups.
The conclusions by NTP on carcinogenicity of benzophenone were: some evidence in male rats
based on the incidence of renal tubule adenoma; equivocal evidence in female rats based on the
marginal increased incidence of mononuclear cell leukaemia (MNCL) and histiocytic sarcoma; some
evidence in male mice based on the increased incidence of hepatocellular adenoma; some evidence in
female mice based on increased incidence of histiocytic sarcoma.
EFSA (2009) noted that benzophenone caused kidney adenoma, including hyperplasia and
nephropathy in rats and applied BMD analysis for the non-neoplastic kidney effects in male rats from
the NTP study (2006) to derive a TDI for benzophenone.
JECFA (2011) noted that histiocytic sarcomas occurred only in female mice and rats and only at dose
levels inducing toxicity and possibly affecting hormonal balance. A NOAEL was not deﬁned. The sex
speciﬁcity of renal pathology in rats was suggested by JECFA to be due to differences in renal clearance of
metabolites and more severe ageing chronic nephropathy in males compared to females, possibly due to
higher concentration of proteins, primarily a-2l-globulin, in male rats. A conclusion from JECFA was that
the increasing severity of ageing chronic nephropathy is largely responsible for the renal tubular
proliferation in male rats and that this mode of action is not relevant to human renal carcinogenesis.
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Overall, in 2-year studies in rats and mice administered benzophenone in the feed, neoplastic
responses were reported in kidney, liver and haematopoietic system. Species- and sex-speciﬁc
differences in effects were observed. Effects were seen in all dose groups and no NOAEL was deﬁned.
3.5.5. Reproductive and developmental toxicity
In a NTP developmental toxicity study, benzophenone was administered by gavage to timed
pregnant rats at doses of 100, 200 or 300 mg/kg bw per day on days 6–19 of gestation (NTP, 2002).
Maternal toxicity was observed at all doses, including clinical signs (lethargy, piloerection, weight loss)
and signiﬁcantly increased maternal liver and kidney weights. Average fetal body weight per litter was
signiﬁcantly lower in the high-dose group compared to controls. No effects on prenatal viability or
overall incidences of fetal malformations were observed. The incidences of unossiﬁed sternebrae were
increased in all dose groups and the incidence of extra rib was increased in the two highest dose
groups. The conclusion was that no NOAEL could be deﬁned, but that the developmental toxicity was
limited to mild developmental delays with a high probability of recovery.
Developmental toxicity of benzophenone was also investigated in rabbits, administered
benzophenone by gavage in doses of 5, 25 and 45 mg/kg bw per day on gestational days 6–29 (NTP,
2004). Maternal body weights and feed consumption decreased in a dose-related manner, but no
effects on liver and kidney weights were observed. There were no effects on prenatal viability.
However, the number of successful deliveries was decreased with increasing dose of benzophenone.
Fetal body weight was signiﬁcantly decreased in the highest dose group. The conclusion by the
authors was that developmental toxicity was only noted in the presence of maternal toxicity.
A two-generation reproductive toxicity study on benzophenone was performed in Sprague–Dawley
rats in accordance with OECD test guideline 416 (OECD, 2001), including extra parameters to detect
endocrine-disrupting activity (Hoshino et al., 2005). Rats were administered benzophenone via feed at
concentrations of 0, 100, 450 or 2,000 mg/kg. According to the authors the corresponding doses were 0,
6.5, 29 and 130 mg/kg bw per day in males and 0, 8.4, 38 and 167 mg/kg bw per day in females of the
F0 generation (Hoshino et al., 2005). In the F1 generation, the parental exposure was somewhat higher.
All exposed groups in the F0 and F1 parental animals had increased liver weights (relative liver
weight increases in the high-dose groups: up to 39% and 32% in F0 and F1 males, respectively, and
up to 49% in the high-dose groups of F0 and F1 females compared with controls) along with a dose-
dependent increase of incidences/severity of centrilobular hepatocytic hypertrophy. However, no
toxicologically relevant liver weight increases were observed in the low-dose group 6.5 mg/kg bw per
day (relative liver weight increase: 4% in the F0 males and females, and 5% and 3% in the groups F1
males and females, respectively, compared with controls). Considering both the induction of CYP
enzymes by benzophenone and the absence of liver tumours in benzophenone-treated rats, the
Panel considers the liver effects as an adaptive response. At the two highest doses, body weight gain
and food consumption were reduced, renal weights were increased, dilatation of renal proximal
tubules and regeneration of proximal tubular epithelium were observed. In the offspring of both F1
and F2, a statistically signiﬁcant decreased body weight gain was reported in males and females of the
highest dose group.
In both generations, no effects were observed on male and female reproduction (sperm analysis,
oestrous cycle, serum levels of testosterone, oestradiol, follicle-stimulating hormone (FSH) and
luteinising hormone (LH), mating and fertility index, gestational length, number of implantation sites,
number of offspring at birth and sex ratio). No effect of treatment was found on viability, physical
development, including vaginal opening and preputial separation of the penis, results of reﬂex and
response tests or on external abnormalities. Anogenital distance (AGD) was statistically signiﬁcantly
decreased in the low- and mid-dose group in females of the F1 generation, but not in the high dose or
in the F2 generation or in males. The decrease in F1 female AGD was up to 11%, statistically signiﬁcant
and based on reasonable numbers (n = 22–24) that accounted for the litter effect. A decreased female
AGD may be adverse and could be an indication of developmental and/or endocrine consequences.
However, the effect on AGD was not dose-dependent and no effects on fertility were observed.
Two-generation reproductive toxicity studies were performed in rats with nine chemicals, including
extra parameters to detect endocrine-disrupting activity (Yamasaki et al., 2005). Rats were given
benzophenone via the diet at concentrations of 0, 100, 450 and 2,000 mg/kg feed, equal to 9, 40.5,
and 180 mg/kg bw per day, using default conversion factors by EFSA (EFSA Scientiﬁc Committee,
2012). According to the authors, no obvious effects on endocrine system and reproductive
toxicological effects were detected in the F0 and F1 parents of F1 and F2 offspring.
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Overall, no effects of benzophenone on reproductive parameters, including reproductive endocrine
system, were demonstrated and developmental effects were only seen in the presence of maternal
toxicity. Concerning the liver effects the CEF Panel reconﬁrms the view of the EFSA opinion 2009 that
liver hypertrophy in rats is an adaptive liver response.
Oestrogenic activity
Data on oestrogenic activity have been addressed in the CEF Panel opinion of 2009 (EFSA, 2009),
IARC (2013) and ECHA (2015). These data are brieﬂy summarised below.
In vitro studies
Oestrogenic activity of benzophenone and its metabolites benzhydrol and 4-hydroxybenzophenone
has been tested in several studies. Nakagawa et al. (2000) treated human breast cancer MCF-7 cells
with 10 nM–500 lM benzophenone or its metabolites for 6 days. Increased cell proliferation, indicating
estrogenic activity, was found at 10–100 lM 4-hydroxybenzophenone, but not after treatment with
benzophenone or benzhydrol. By using oestrogen competitive ligand binding assay Nakagawa and
Tayama (2001) demonstrated binding of 4-hydroxybenzophenone (IC50 50 lM), but no binding of
benzophenone or benzhydrol at concentrations up to 500 lM. Reporter gene assays, measuring
oestrogen receptor-alpha (ERa) activity, was negative for benzophenone and positive for 4-
hydroxybenzophenone (Yamasaki et al., 2002; Suzuki et al., 2005; Kerdivel et al., 2013). In two more
recent studies, benzophenone showed a weak oestrogenic potency (more than ﬁve orders of
magnitude less potent that 17b-estradiol) in the yeast oestrogen (YES) assay (Zhang et al., 2017) and
in a chemokine (CXCL12 as an indicator of oestrogen-dependent proliferation) releasing assay in breast
cancer cells (Habauzit et al., 2017). The latter report showed that 4-hydroxybenzophenone is more
potent than benzophenone which is qualitatively in line with the above reported ﬁndings.
In vivo studies
The rat uterotrophic assay (OECD test guideline 440, 2007) has been used to test oestrogenic
activity of benzophenone and its metabolites in vivo. Yamasaki et al. (2002) did not observe any
effects in the immature rat uterotrophic assay, when benzophenone was injected subcutaneously at
doses of 2, 20 and 200 mg/kg bw for 3 days. In contrast, Nakagawa and Tayama (2002)
demonstrated oestrogenic activity of benzophenone in a study with ovariectomised rats. Sprague–
Dawley rats were administered benzophenone orally at doses of 100 or 400 mg/kg bw per day for 3
days. The high dose resulted in increased uterine weight as well as an increase in luminal epithelial
height and stromal cells in the uterus and an increase in thickness of vaginal epithelial cell layers with
corniﬁcation.
The same authors reported a dose-dependent increase in uterine weight in juvenile female rats
administered 4-hydroxybenzophenone subcutaneously in doses of 100, 200 and 400 mg/kg bw for 3
days (Nakagawa and Tayama, 2001). The uterine response was accompanied by an increase in luminal
epithelial height and stromal cells in the uterus and an increase in thickness of vaginal epithelial cell
layers with corniﬁcation. No effects were observed after treatment with benzophenone or benzhydrol
at 400 mg/kg bw. Yamasaki et al. (2003) demonstrated a dose-related increase in uterine weight at
doses ≥ 200 mg/kg bw of 4-hydroxybenzophenone, injected subcutaneously for 3 days in juvenile rats.
In summary, oestrogenic activity of 4-hydroxybenzophenone, but not of benzophenone or the main
metabolite benzhydrol, was demonstrated in in vitro and in vivo model systems, i.e. uterotrophic assay,
except in one assay with ovariectomised rats at a high dose of benzophenone or at high
concentrations in vitro which are of questionable relevance for risk assessment. The Panel noted that
reproductive and developmental toxicity studies on benzophenone, including extra parameters to
detect endocrine-disrupting activity of benzophenone, did not detect any obvious effects on endocrine
system and reproductive toxicity despite the demonstrated oestrogenic activity of its metabolite 4-
hydroxybenzophenone.
3.5.6. Other endocrine effects
Anti-androgenic activity of 4-hydroxybenzophenone and benzophenone was reported by Suzuki
et al. (2005) in an in vitro study using a reporter gene assay, where the inhibitory effect of the test
compounds on the androgenic activity of dihydrotestosterone was examined.
No androgenic activity of 4-hydroxybenzophenone was demonstrated, in vivo, studied in rats by the
Hershberger assay (Yamasaki et al., 2003).
Safety of benzophenone
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2017;15(11):5013
An inhibitory effect of benzophenone on thyroid peroxidase activity, in vitro, although without a
clear dose-response, was reported by Song et al. (2012), using a reporter gene assay.
Using the yeast two-hybrid assay, Mikamo et al. (2003) showed that benzophenone activated
pregnane X receptor (PXR) in vitro. The same authors also reported that benzophenone induced
CYP2C11, CYP2B1/2 and CYP3A1 gene expression in liver of rats administered with benzophenone by
intraperitoneal injection for 3 days. The Panel considers that this might affect levels of endogenous
hormones via the production of active metabolites.
3.5.7. Derivation of a TDI
According to the CEF Panel opinion of 2009 (EFSA, 2009), liver and kidney were identiﬁed as the
primary target organs of benzophenone toxicity in rats and in mice, based on results from chronic
carcinogenicity (NTP, 2006) and reproductive toxicity studies (Hoshino et al., 2005).
Liver hypertrophy in the rat at the lowest dose level (~ 6 mg/kg bw per day) in a two-generation
study (Hoshino et al., 2005) was considered the most sensitive effect of benzophenone. However, in
the absence of liver tumours in rats in the chronic NTP carcinogenicity study (even at doses yielding
severe liver damage), the Panel concluded that the liver hypertrophy in rat is an adaptive but not an
adverse response as also discussed by Maronpot et al. (2010) and by Hall et al. (2012).
While benzophenone caused liver adenomas in the B6C3F1 mouse, at a dose of 40 mg/kg bw per
day, the Panel noted that this effect is a less sensitive endpoint than the kidney effects in rats at the
lowest dose of 15 mg/kg bw per day in a chronic carcinogenicity study (NTP, 2006). Along with dose-
related increases in the incidences of renal tubule hyperplasia and in the severity of chronic
nephropathy, a positive trend in the incidences of renal tubule adenoma was observed in the male
rats. In female rats, the severity of nephropathy was signiﬁcantly increased in the mid and high dose
groups. Given that proliferative lesions and adenomas may be considered as a biological and
morphological continuum in the progression to kidney neoplasia and the contribution of nephropathy
to kidney tumour development cannot be ruled out (Rhodes et al., 2007; Melnick et al., 2012), the
Panel considered that the non-neoplastic effects are adverse and used them as a point of departure
for the risk assessment of benzophenone. As reported in the CEF Panel opinion (EFSA, 2009)
‘Benchmark dose (BMD) analyses were applied for the non-neoplastic kidney effects in male rats (NTP,
2006), and the lower 95% conﬁdence limits of the benchmark dose for a 10% effect (BMDL10) were
calculated to be 3.1–7.4 mg/kg b.w. per day. The models used in the analysis were consistent, and
passed statistical validation. The Panel decided that the BMDL10 value of 3.1 mg/kg b.w. per day was
the most appropriate departure point for derivation of the TDI. By applying an uncertainty factor of
100, a TDI of 0.03 mg/kg body weight is derived’. Based on the incidence data for non-neoplastic
kidney effects, the BMDL was recalculated in accordance to the update on the use of the BMD
approach (EFSA Scientiﬁc Committee, 2017) using the EFSA web-tool5 and the same BMDL was
obtained as in the previous assessment (Appendix D). In the light of an ongoing debate on the
relevance of the rat chronic nephropathy to humans (Melnick et al., 2012; Hard et al., 2013), the
Panel considers the EFSA approach used in the 2009 opinion to derive a TDI for benzophenone
conservative and appropriate to cover the potential induction of toxic effects including tumours in
humans.
3.5.8. Discussion
In the NTP carcinogenicity studies with rats and mice, tumour induction by benzophenone was
observed in liver, kidney and the haematopoietic system. The Panel concluded that based on the
negative results from studies on mutagenicity or chromosomal damage a genotoxic mechanism of
tumour induction by benzophenone can be excluded. A potential involvement of endocrine effects of
benzophenone or its metabolite 4-hydroxybenzophenone in tumour induction, e.g. via oestrogenic,
anti-androgenic modulation or the potential activation of nuclear constitutive androstane receptor and
PXR (as discussed e.g. by IARC and ECHA) cannot be ruled out. However, the Panel noted that the
effective concentrations of these substances in vitro and the effective dose of benzophenone in the
uterotrophic assay with ovariectomised rats were relatively high indicating only weak endocrine effects.
In addition, the Panel noted that no oestrogenic effects of benzophenone were reported in (sub)
chronic, reproductive and developmental toxicity studies. The Panel noted that there is no concern
with respect to genotoxicity. Accordingly, a threshold mechanism of toxicity can be assumed.
5 https://shiny-efsa.openanalytics.eu/
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Therefore, the Panel concludes that the carcinogenicity is also covered by the TDI (0.03 mg/kg bw)
derived from the most sensitive endpoint, non-neoplastic effects of benzophenone in rat kidneys
observed in the chronic NTP study (NTP, 2006).
The incidences of histiocytic sarcoma observed in female rats and mice in the NTP carcinogenicity
study showed positive trends. Histiocytic sarcomas are considered as extremely rare neoplasms in mice
(historical control range for feed studies: 0–2%) and rats (not observed in historical controls). This
neoplastic lesion was observed at 625 mg/kg feed (mice: 80 and 70 mg/kg bw per day for males and
females, respectively, and rats: 30 mg/kg bw per day) and 1,250 mg/kg feed (mice: 160 and 150 mg/kg
bw per day for males and females, respectively, and rats: 60 and 65 mg/kg bw per day for males and
females, respectively). The low incidences of this lesion (3/50 and 2/50 at the highest doses in mice and
rats, respectively) are associated with a high uncertainty in risk assessment.
A statistically signiﬁcant increase in the incidences of MNCL was observed in male rats in the low-
(15 mg/kg bw per day) and in the mid- (30 mg/kg bw per day) dose groups, whereas the incidences at
the highest dose (60 mg/kg bw per day) in males were slightly decreased compared to controls. In
female rats, the incidence of MNCL exceeded the historical control range with a signiﬁcant increase in
the mid-dose group. An extended assessment of the lesions in males showed that the extent of multiple
organ involvement of leukaemia decreased in the higher exposure groups (Rhodes et al., 2007). The
Panel noted that while MNCL is a common neoplasm in F344 rats used in the NTP study, it is species-
speciﬁc and no histological comparable tumour is observed in humans. Thus, this tumour may not be
appropriate for human health risk assessment (Maronpot et al., 2016).
In the NTP (2006) carcinogenicity study with mice, there was a positive trend in the incidence of
hepatocellular adenoma in males. Moreover, IARC (2013) also noted that hepatoblastomas in the high-
dose group of males – even though not statistically different from controls – exceeded the historical
control range. In addition, non-neoplastic lesions in the livers were signiﬁcantly increased in mice. In
contrast to mice, no liver tumours were reported for rats while the hypertrophic effect of
benzophenone in the liver was observed in the Hoshino study (Hoshino et al., 2005) at all doses.
Considering that no neoplastic liver lesions were observed in rats, the CEF Panel reconﬁrms the view of
the EFSA 2009 opinion that benzophenone-induced liver hypertrophy is an adaptive response, i.e. not
adverse (Maronpot et al., 2010; Hall et al., 2012).
In the NTP (2006) carcinogenicity study, treatment-related increases in the severity of chronic
nephropathy, in the incidences of renal tubule adenomas and renal tubule hyperplasia were reported.
The potential impact of nephropathy to the formation of neoplastic lesions in the kidney was noted by
several authors (Seely et al., 2002; Rhodes et al., 2007; Travlos et al., 2011) while the relevance of the
rat chronic nephropathy to humans was discussed controversially (Melnick et al., 2012; Hard et al.,
2013). For the risk assessment of benzophenone, the Panel considered the statistically signiﬁcant
increases in renal tubule hyperplasia in all treated males and females (single and step sections,
combined) as an adverse effect and reconﬁrmed as a conservative approach the lowest BMDL10 of
3.1 mg/kg bw per day derived in the EFSA 2009 opinion. Having applied the usual uncertainty factor
of 100 to the BMDL10, the Panel considers the resulting TDI of 0.03 mg/kg bw sufﬁcient to cover
neoplastic effects induced in the rodent carcinogenicity studies observed at 40 mg/kg bw per day and
above.
4. Conclusions
Based on the negative results from studies on the relevant genetic endpoints, the Panel concluded
that there is no concern with respect to genotoxicity of benzophenone.
Having reviewed the data related to endocrine activities of benzophenone and its metabolite 4-
hydroxybenzophenone, the Panel considered them as weak and not directly related to the observed
toxic effects including the neoplastic effects of these substances.
Overall, the Panel concludes that the conservative approach taken by the CEF Panel in 2009 (EFSA,
2009) to derive a TDI of 0.03 mg/kg bw for benzophenone is appropriate to cover the non-neoplastic
effects in the chronic toxicity studies and the neoplastic effects induced in the rodent carcinogenicity
studies.
The Panel notes that the TDI is in the same order of magnitude as the chronic dietary exposure of
adults and children to benzophenone (10–20 lg/kg bw per day) calculated by the APET approach for
the amount of added ﬂavouring. The Panel considers that the calculated TDI and exposure estimate
are based on conservative assumptions. The Panel concludes that there is no safety concern for
benzophenone under the current condition of use as a ﬂavouring substance.
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5. Recommendations
The Panel takes note of other potential sources of dietary exposure such as from FCM. Exposure
from FCM could be up to 10 lg/kg bw per day, bringing the potential exposure from both plastic and
ﬂavouring up to the TDI for children. The Commission may wish to take this into account.
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Appendix A – Genotoxicity data evaluated in FGE.69
Table A.1: Genotoxicity data on benzophenone [FL-no: 07.032] evaluated by JECFA (2002) and considered by EFSA in FGE.69 (2008)
Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
Benzophenone
07.032
831
Bacterial reverse
mutation
S. Typhimurium TA97, TA98,
TA100, TA1535 and TA1537
3–1,000 lg/plate Negative(a) Mortelmans et al. (1986) Reliable with the following
restriction: the study complied with
current recommendations with the
exception that tester strains TA102
or E. coli WP2uvrA were not used
(a): With and without metabolic activation.
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Appendix B – Previously not considered genotoxicity data
Table B.1: In vitro genotoxicity studies on benzophenone [FL-no: 07.032]
Chemical name
FL-no
JECFA-no
End-point Test system Concentration Results Reference Comments
Benzophenone
07.032
831
SOS/umuC assay S. Typhimurium
TA1535
0–1,000 lM(a) Positive Takemoto et al. (2002) Study is reliable. Positive at the higher
concentrations (100–1,000 lM) in the
presence of metabolic activation.
However, the relevance of this
endpoint is low
7.8–1,000 lg/mL(a) Positive Kotnik et al. (2016) Study is reliable. Positive at the highest
concentration in the presence of
metabolic activation. However, the
relevance of this endpoint is low
Bacterial reverse
mutation assay
S. Typhimurium
TA98, TA100,
TA1535, TA1537
10–2,000 lg/plate(a),(d) Negative CCRIS (2009) Reliability cannot be evaluated
(full study report not available)3–333 lg/plate(b),(e) Negative
10–1,000 lg/plate(b),(e) Negative
1–166 lg/plate(c),(e) Negative
Gene mutation in
mammalian cells
L5178Y (tk+/)
mouse lymphoma
cells
33–90 lg/mL(c)
35–145 lg/mL(b)
Negative
8.9–142.8 lg/mL(c)
8.9–141.7 lg/mL(b)
Negative Jeon et al. (2007) Reliable with limitations (experimental
details are not provided)
80% inhibitory concentration (IC80)
was used as maximum concentration
(a): With and without metabolic activation.
(b): With metabolic activation.
(c): Without metabolic activation.
(d): Plate-incorporation.
(e): Pre-incubation.
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Table B.2: In vivo genotoxicity studies on benzophenone [FL-no: 07.032]
Chemical name
FL-no
JECFA-no
Test system in vivo Test object Route Dose Result Reference Comments
Benzophenone
07.032
831
Micronucleus assay
in bone marrow
B6C3F1 male mice Intraperitoneal 200, 300, 400,
500 mg/kg bw
(solvent: corn oil)
Negative NTP (2006) Reliable without restriction. Three
injections at 24 h intervals;
sacriﬁce 24 h after 3rd injection.
No toxicity to the bone marrow
Micronucleus assay in
peripheral blood
polychromatic
erythrocytes
B6C3F1 male and
female mice
Oral (feed) 1,250, 2,500,
5,000, 10,000,
20,000 ppm
Negative Reliable without restriction.
Harvest at end of 14-week
dosing regimen. No toxicity to the
bone marrow
Male CBA mice Intraperitoneal 500, 1,000,
2,000 mg/kg bw
Negative Abramsson-
Zetterberg
and Svensson
(2011)
Reliable without restriction.
Single intraperitoneal injection,
peripheral blood sampled after 42 h
Male NMRI mice 100, 250, 400,
600 mg/kg bw
Negative Reliable without restriction.
Single intraperitoneal injection,
peripheral blood sampled after 42 h
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Appendix C – Exposure
Calculation of the Dietary Exposure - APET
Chronic Dietary Exposure – ‘Added Portions Exposure Technique’ (APET)6
The chronic APET calculations are based on the normal combined occurrence level by adding the
highest contributing portion of food and highest contributing portion of beverages (either among soft
drinks or alcoholic beverages). APET for children is calculated by adding the highest contributing
portion of food and highest contributing portion of beverages (among soft drinks). Furthermore, in the
APET calculation for children the portion sizes listed in Table C.1 is adjusted by a factor 0.63 to take
into account the smaller portion sizes consumed by the child.
Adults (‘Added Portions Exposure Technique’ (APET))
On the basis of normal occurrence level from the added ﬂavouring only
Solid Food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 212 lg/adult per day.
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of 300 lg/adult per
day.
The total APET will be 512 lg/adult per day corresponding to 8.5 lg/kg bw per day for a 60-kg
person.
Children (3-year-old child of 15 kg body weight)
Solid Food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 212 9 0.63 = 134 lg/child per day.
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of
300 9 0.63 = 189 lg/child per day.
The total APET will be 323 lg/child per day corresponding to 22 lg/kg bw per day for a 15-kg
child.
Conclusion
The higher of the two values among adults and children, expressed per kg/bw per day, should be
used as the basis for the safety evaluation of the candidate substance, i.e. the value of 22 lg/kg bw
per day for a 15-kg child should be compared to the appropriate NOAEL for the candidate substance.
Combined Dietary Exposure
This is an estimate of total dietary exposure deriving from both the addition of the ﬂavouring
substance to foods and beverages and other dietary sources. To estimate the APET for combined
dietary exposure, the occurrence of the substance in grapes and vanilla was also taken into account in
the estimation.
Adults (‘Added Portions Exposure Technique’ (APET))
On the basis of normal occurrence level from the added ﬂavouring only
Solid Food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 212 lg/adult per day.
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of 300 lg/adult per
day.
The total APET will be 512 lg/adult per day corresponding to 8.5 lg/kg bw per day for a 60-kg
person.
6 The APET has been calculated based on the occurrence levels in the food sub-categories reported in the above table, with the
exclusion of categories 13.2 (complementary foods for infants and young children).
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Children (3-year-old child of 15 kg body weight)
Solid Food: The maximum intake will be from category 1.0 (Dairy products) with the normal
combined occurrence level of 212 9 0.63 = 134 lg/child per day.
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the
candidate substance is added have the same normal combined occurrence level of 300 9 0.63 = 189
lg/child per day.
The total APET will be 323 lg/child per day corresponding to 22 lg/kg bw per day for a 15-kg
child.
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Table C.1: Normal and maximum occurrence levels for reﬁned categories of foods and beverages
Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
01.1 Milk- and dairy-based drinks 200 1.06 5 1.06 5
01.2 Fermented and renneted milk products (plain), excluding food
category 01.1.2 (dairy-based drinks)
200 1.06 5 1.06 5
01.3 Condensed milk and analogues (plain) 70 1.06 5 1.06 5
01.4 Cream (plain) and the like 15 1.06 5 1.06 5
01.5 Milk powder and cream powder and powder analogues (plain) 30 1.06 5 1.06 5
01.6 Cheese and analogues 40 1.06 5 1.06 5
01.7 Dairy-based desserts (e.g., pudding, fruit or ﬂavoured yoghurt) 125 1.06 5 1.06 5
01.8 Whey and whey products, excluding whey cheeses 200 1.06 5 1.06 5
02.1 Fats and oils essentially free from water 15
02.2 Fat emulsions mainly of type water-in-oil 15
02.3 Fat emulsions mainly of type water-in-oil, including mixed
and/or ﬂavoured products based on fat emulsions
15
02.4 Fat-based desserts excluding dairy-based dessert products of
category 1.7
50
03.0 Edible ices, including sherbet and sorbet 50 0.01 0.089 0.01 0.089
04.1.1 Fresh fruit 140 0.13 0.13
04.1.2 Processed fruit 125 0.13 0.13
04.1.2.5 Jams, jellies, marmalades 30
04.2.1 Fresh vegetables (including mushrooms and fungi, roots and
tubers, pulses and legumes, and aloe vera), seaweed, and nut
and seed
200
04.2.2 Processed vegetables (including mushrooms and fungi, roots
and tubers, pulses and legumes, and aloe vera), seaweed,
and nut and seed purees and spreads (e.g. peanut butter) and
nuts and seeds
200
04.2.2.5 Vegetables (including mushrooms and fungi, roots and tubers,
pulses and legumes, and aloe vera), seaweed, and nut and seed
purees and spreads (e.g. peanut butter)
30
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
05.1 Cocoa products and chocolate products, including imitations
and chocolate substitutes
40 1.15 2.42 1.15 2.42
05.1.3 Cocoa-based spreads, including ﬁllings 30 1.15 2.42 1.15 2.42
05.2 Confectionery, including hard and soft candy, nougats, etc.,
other than 05.1, 05.3 and 05.4
30 1.15 2.42 1.15 2.42
05.3 Chewing gum 3
05.4 Decorations (e.g. for ﬁne bakery wares), toppings (non-fruit)
and sweet sauces
35 1.15 2.42 1.15 2.42
06.1 Whole, broken or ﬂaked grain, including rice 200 1 5 1 5
06.2 Flours and starches (including soya bean powder) 30 1 5 1 5
06.3 Breakfast cereals, including rolled oats 30 1 5 1 5
06.4 Pastas and noodles and like products (e.g. rice paper, rice
vermicelli, soya bean pastas and noodles)
200 1 5 1 5
06.5 Cereal- and starch-based desserts (e.g. rice pudding, tapioca
pudding)
200 1 5 1 5
06.6 Batters (e.g. for breading or batters for ﬁsh or poultry) 30 1 5 1 5
06.7 Pre-cooked or processed rice products, including rice cakes
(Oriental type only)
200 1 5 1 5
06.8 Soya bean products (excluding soya bean products of food
category 12.9 and fermented soya bean products of food
category 12.10)
100 1 5 1 5
07.1 Bread and ordinary bakery wares 50 1 5 1 5
07.2 Fine bakery wares (sweet, salty, savoury) and mixes 80 1 5 1 5
08.1 Fresh meat, poultry and game 200
08.2 Processed meat, poultry and game products in whole
pieces or cuts
100
08.3 Processed comminute meat, poultry and game products 100
08.4 Edible casings (e.g. sausage casings) 1
09.1.1 Fresh ﬁsh 200
09.1.2 Fresh molluscs, crustaceans and echinoderms 200
Safety of benzophenone
www.efsa.europa.eu/efsajournal 24 EFSA Journal 2017;15(11):5013
Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
09.2 Processed ﬁsh and ﬁsh products, including molluscs,
crustaceans and echinoderms
100
09.3 Semi-preserved ﬁsh and ﬁsh products, including molluscs,
crustaceans and echinoderms
100
09.4 Fully preserved, including canned or fermented, ﬁsh and ﬁsh
products, including molluscs, crustaceans and echinoderms
100
10.1 Fresh eggs 100 1 5 1 5
10.2 Egg products 100 1 5 1 5
10.3 Preserved eggs, including alkaline. salted and canned eggs 100 1 5 1 5
10.4 Egg-based desserts (e.g. custard) 125 1 5 1 5
11.1 Reﬁned and raw sugar 10
11.2 Brown sugar excluding products of food category 11.1 10
11.3 Sugar solutions and syrups, and (partially) inverted sugars,
including molasses and treacle, excluding products of food
category 11.1.3 (soft white sugar, soft brown sugar, glucose
syrup, dried glucose syrup, raw cane sugar)
30
11.4 Other sugars and syrups (e.g. xylose, maple syrup, sugar
toppings)
30
11.5 Honey 15
11.6 Table-top sweeteners, including those containing high-intensity
sweeteners
1
12.1 Salt and salt substitutes 1
12.10 Protein products other than from soybeans 15
12.2 Herbs, spices, seasonings and condiments (e.g. seasoning for
instant noodles)
1 0.48 0.48
12.3 Vinegars 15
12.4 Mustards 15
12.5 Soups and broths 200
12.6 Sauces and like products 30
12.7.a Salads 120 g (e.g. macaroni salad, potato salad) excluding
cocoa- and nut-based spreads of food categories
120
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
12.7.b Sandwich spreads (20 g), excluding cocoa- and nut-based
spreads of food categories
20
12.8 Yeast and like products 1
12.9 Soybean-based seasonings and condiments 15
12.9.1 Fermented soya bean products (e.g. miso) 40
12.9.2 Soybean sauce 15
12.9.3 Fermented soybean sauce 15
13.2.a Complementary foods for infants and young children:
Dry instant cereals (with or without milk), including pasta
110
13.2.b Complementary foods for infants and young children:
Meat-based or ﬁsh-based dinner
170
13.2.c Complementary foods for infants and young children:
Dairy-based dessert
110
13.2.d Complementary foods for infants and young children:
Vegetables, potatoes, broth, soups, pulses
170
13.2.e Complementary foods for infants and young children:
Biscuits and cookies
20
13.2.f Complementary foods for infants and young children:
Fruit puree
110
13.2.g Complementary foods for infants and young children:
Fruit juice
120
13.2.h Milk for young children 200
13.3 Dietetic foods intended for special medical purposes (excluding
food products of category 13.1 ‘Infant formulae, follow-up formulae
and other formulae for special medical purposes for infants’)
200 1 5 1 5
13.4 Dietetic formulae for slimming purposes and weight reduction 200 1 5 1 5
13.5 Dietetic foods (e.g. supplementary foods for
dietary use), excluding products of food
categories 13.1 (Infant formulae, follow-up
formulae and other formulae for special medical
purposes for infants), 13.2–13.4 and 13.6
200 1 5 1 5
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Food categories(a)
Standard
portions(b) (g)
Occurrence level as
added ﬂavouring
substance (mg/kg)
Occurrence level
from other
sources(c) (mg/kg)
Combined occurrence
level from all
sources(e) (mg/kg)
Normal Maximum Average(d) Maximum Normal Maximum
13.6 Food supplements 5
14.1 Other non-alcoholic (‘soft’) beverages (expressed as liquid) 300 1 5 1 5
14.2.1 Beer and malt beverages 300
14.2.2 Cider and perry 300
14.2.3 Grape wines 150
14.2.4 Wines (other than grape) 150
14.2.5 Mead 150
14.2.6 Distilled spirituous beverages containing more than 15% alcohol 30
14.2.7 Aromatised alcoholic beverages (e.g. beer, wine and spirituous
cooler-type beverages, low alcoholic refreshers)
300
15.1 Snacks, potato-, cereal-, ﬂour- or starch-based (from roots and
tubers, pulses and legumes)
30
15.2 Processed nuts, including coated nuts and nut mixtures
(with e.g. dried fruit)
30
15.3 Snacks – ﬁsh-based 30
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) –
foods that could not be placed in categories 01–15
300 0.02 0.15 0.02 0.15
(a): Most of the categories reported are the sub-categories of Codex GSFA (General Standard for Food Additives, available at http://www.codexalimentarius.net/gsfaonline/CXS_192e.pdf) used by
the JECFA in the SPET technique (FAO/WHO, 2008). In the case of category 13.2 (complementary foods for infants and young children), further reﬁned categories have been created so that a
speciﬁc assessment of dietary exposure can be performed in young children.
(b): For Adults. In case of foods marketed as powder or as concentrates, occurrence levels must be reported for the reconstituted product, considering the instructions reported on the product
label or one of the standard dilution factors established by the JECFA (FAO/WHO 2008):
– 1/25 for powder used to prepare water-based drinks such as coffee, containing no additional ingredients,
– 1/10 for powder used to prepare water-based drinks containing additional ingredients such as sugars (ice tea, squashes, etc.),
– 1/7 for powder used to prepare milk, soups and puddings,
– 1/3 for condensed milk.
(c): As natural constituent and/or developed during the processing and/or as carry over resulting from their use in animal feed.
(d): In order to estimate normal values in each category, only foods and beverages in which the substance is present in signiﬁcant amount will be considered (e.g. for the category ‘Fresh fruit’
04.1.1., the normal concentration will be the median concentration observed in all kinds of fruit where the ﬂavouring substance is known to occur).
(e): As added ﬂavouring or from other sources. The normal and maximum combined occurrence levels of the substance will be assessed by the applicant either by adding up occurrence levels from
added use to that from other sources or by expert judgement based on the likelihood of their concomitant presence. This will be done both for normal use levels and for maximum use levels.
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Appendix D – Benchmark Dose Modelling: Report
Data description
The endpoint to be analysed is: pelvis, transitional epithelium hyperplasia.
Data used for analysis:
Dose Hyperepith Total
0 1 50
15 11 50
30 29 50
60 34 50
Selection of the BMR
The benchmark dose (BMD) is deﬁned as the dose that corresponds with an extra risk of 10%
compared with the background risk. The benchmark response (BMR) is the estimated risk
corresponding with the BMD of interest.
A 90% conﬁdence interval around the BMD will be estimated, the lower bound is reported by BMDL
and the upper bound by BMDU.
Software used
Results are obtained using the EFSA web-tool for BMD analysis
• Fitting benchmark dose models is based on the R-package PROAST, version 64.9.
• Averaging results from multiple ﬁtted benchmark dose models is based on the methodology in
Wheeler and Bailer (2008).
Speciﬁcation of deviations from default assumptions
None.
Dose–response models
Default set of ﬁtted models:
Model Number of parameters Formula
Null 1 y = a
Full No. of groups y = group mean
Logistic 2 y ¼ 1
1þ expða bxÞ
Probit 2 y ¼ pnormððx aÞ  bÞ
Log-logistic 3 y ¼ aþ 1 a
1þ exp

c  log

b
x

Log-probit 3 y ¼ aþ ð1 aÞ  pnorm

c  log

x
b

Weibull 3 y ¼ aþ ð1 aÞ

1 exp



x
b
c
Gamma 3 y = pgamma(bx; c)
Two-stage 3 y ¼ aþ ð1 aÞ

1 exp

 xb c

x
b
2
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2017;15(11):5013
Safety of benzophenone
Procedure for selection of BMDL
Flow chart for selection of BMDL
Safety of benzophenone
www.efsa.europa.eu/efsajournal 29 EFSA Journal 2017;15(11):5013
Results
Response variable: Hyperepith
Fitted Models
Model No.par loglik AIC accepted BMDL BMDU BMD conv
null 1 132.31 266.62 NA NA NA NA
full 4 96.61 201.22 NA NA NA NA
two.stage 3 98.40 202.80 Yes 4.13 6.29 5.1 Yes
log.logist 3 97.92 201.84 Yes 2.90 11.20 7.0 Yes
Weibull 3 98.40 202.80 Yes 1.59 9.33 5.1 Yes
log.prob 3 97.90 201.80 Yes 3.38 11.80 7.7 Yes
gamma 3 98.40 202.80 Yes 1.29 10.20 5.3 Yes
logistic 2 104.29 212.58 No NA NA 13.0 Yes
probit 2 103.78 211.56 No NA NA 12.0 Yes
LVM: Expon. m5- 4 96.61 201.22 Yes 5.30 14.60 11.0 Yes
LVM: Hill m5- 4 96.61 201.22 Yes 5.76 14.70 12.0 Yes
Estimated model parameters
two.stage
estimate for a-: 0.01894
estimate for BMD-: 5.05
estimate for c: 1e-06
log.logist
estimate for a-: 0.019
estimate for BMD-: 7.026
estimate for c: 1.462
Weibull
estimate for a-: 0.01895
estimate for BMD-: 5.064
estimate for c: 1.001
log.prob
estimate for a-: 0.0192
estimate for BMD-: 7.662
estimate for c: 0.9019
gamma
estimate for a-: 0.01916
estimate for BMD-: 5.337
estimate for cc: 1.038
logistic
estimate for a-: -2.078
estimate for BMD-: 12.6
probit
estimate for a-: -1.286
estimate for BMD-: 12.04
EXP
estimate for a-: 1.671
estimate for CED-: 10.88
estimate for c-: 0.5321
estimate for d-: 1.527
estimate for th: 0
estimate for sigma: 0.25
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HILL
estimate for a-: 1.671
estimate for CED-: 11.87
estimate for c-: 0.526
estimate for d-: 2.871
estimate for th: 0
estimate for sigma: 0.25
Weights for Model Averaging
two.stage log.logist Weibull log.prob gamma logistic probit EXP HILL
0.09 0.15 0.09 0.15 0.09 0 0 0.21 0.21
Final BMD Values
BMD BMDL BMDU
8.4 3.1 13
Conﬁdence intervals for the BMD are based on 200 generated data sets.
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